Duality Biotherapeutics Passes HKEX Listing Hearing and Set for IPO; HER2 ADC New Drug Expected to File for FDA Approval in 2025

DualityBio: Passed the Hong Kong Stock Exchange Listing Hearing, Going Public Soon

DualityBio Has Passed the Hearing of HKEX and Is About to Be Listed, with a Rich ADC Pipeline and Technology Platform, Reaching Licensing Cooperation with Multiple Enterprises. Its HER2 ADC New Drug is Expected to Submit an Application for Marketing Approval to the FDA in 2025, Which is Likely to Become the First China-produced ADC New Drug in the United States, While Also Submitting an Application for the Treatment of Breast Cancer in China. (Source: Sina Finance)

"First Stock in Growth and Development of Hong Kong Stocks" Rings the Bell for Listing!

After updating the prospectus, VISEN Pharmaceuticals, the only港股专注于内分泌领域并研发长效生长激素的公司 in Hong Kong, officially listed on the Hong Kong Stock Exchange. As a rare and purely endocrine innovation-focused company in the港股 market, VISEN Pharmaceuticals has been continuously attracting significant market attention since its filing, earning the title of "the first growth and development stock in港股." VISEN Pharmaceuticals is a late-stage biopharmaceutical company with products nearing commercialization, focusing on the endocrine field and committed to providing first-in-class or best-in-class products and treatment solutions for endocrine diseases. (Source: Sina Finance)

BAICHUAN AI Collaborates with Beijing Children's Hospital to Launch the World's First Pediatric Large Model and Two AI Pediatricians

On March 20, BAICHUAN AI, Beijing Children's Hospital, and Xiaoaofang Health jointly released the world's first pediatric large model — "Futang·Baichuan" Pediatric Large Model. This model not only covers a three-dimensional knowledge system of common and difficult pediatric diseases but also possesses strong clinical reasoning capabilities in pediatrics. It also pioneered the pediatric "evidence-based model," which can integrate the best medical evidence like a professional pediatrician to formulate scientific and personalized treatment plans for young patients. (Source: Arterial Network)

$55 Billion: Johnson & Johnson Announces Major Move

Johnson & Johnson (NYSE:JNJ), the leading and most comprehensive innovator in the healthcare industry, announced that it will invest over $55 billion in manufacturing, research and development, and technology in the United States over the next four years. This represents a 25% increase in investment compared to the previous four years and builds on the company’s already elevated U.S. investment levels following the passage of the 2017 Tax Cuts and Jobs Act. Johnson & Johnson operates more manufacturing facilities in the U.S. than in any other country and is a leading investor in American innovation and R&D. The company focuses on pharmaceuticals and medical technologies, making a unique impact on various diseases. (Source: Arterial Network)

ANDA BIOPHARMA Completes Series A Financing of Tens of Millions of Yuan

Breakthrough Progress in the Field of Precision Oncology. ANDA BIOPHARMA (Shenzhen) Co., Ltd. ("ANDA BIOPHARMA") announced the completion of a multi-million yuan Series A round of financing. This round was led by Liding Capital and Puyao Xinye, with participation from Lincang Sinan, Botong Venture Capital, and DFJ Dragon Fund. The proceeds will be primarily used to advance the clinical research of its core pipeline—the personalized tumor neoantigen vaccine PCNAT-01—and to expedite the preclinical development of other projects in the pipeline. (Source: Arterial Network)

Yilin Cloud Completes New Round of Financing Worth Tens of Millions in Capital Winter

Recently, Yilin Cloud (Ningbo) Technology Co., Ltd. ("Yilin Cloud") announced the completion of a new round of financing worth tens of millions of yuan, led exclusively by the well-known biopharmaceutical investment institution Hongfeng Investment. Against the backdrop of a global capital winter, this round of financing not only highlights Yilin Cloud's strong capabilities in AI-driven clinical research but also marks a solid step forward in the company’s journey to promote intelligent transformation within the industry. (Source: Arterial Network)

Fire Eye Jingjing Completes Nearly RMB 10 Million Angel Round Financing

Shenzhen Huoyanjing Medical Technology Co., Ltd. (referred to as "Huoyanjing"), which focuses on the digital optometry field, announced the completion of an angel round of financing worth nearly ten million yuan, exclusively invested by Times Bole. This round of financing will accelerate Huoyanjing's R&D iteration and market expansion in the XR intelligent medical field for eye optometry, promoting myopia prevention and control technology for children and adolescents into a new intelligent stage. (Source: Arterial Network)

Easylive completes seed round financing

Hefei Yilian Litong Medical Technology Co., Ltd. ("Yilian Litong" for short) has recently completed its seed round of financing, jointly invested by Hefei Industry Investment Guozheng and Hefei Baohe Venture Capital, with Xuyi Capital serving as the long-term financial advisor. This round of financing will be used to accelerate the mass production verification, clinical research of the company's core product "Kunpeng" second-generation suspension system, and the research and development upgrade of the third-generation products, further consolidating its leading position in the field of minimally invasive treatment for benign prostatic hyperplasia (BPH). (Source: Arterial Network)

Xikang Cloud Hospital Announces 2024 Annual Results

On March 20, Xikang Cloud Hospital released its 2024 annual performance announcement. According to the announcement, in 2024, the company achieved revenue of approximately RMB 501 million; gross profit of approximately RMB 147 million, with a gross margin of about 29.4%; adjusted net loss of approximately RMB 75 million, narrowing significantly by 34.8% year-over-year, indicating that profitability is expected to accelerate. The financial condition for the entire year improved significantly, with operating net cash flow of approximately RMB 21.56 million, turning positive for the first time. (Source: Arterial Network)

Hunan Provincial Medical Insurance Bureau Issues the "Notice on Carrying Out Price Correction for the First Batch of Listed Drugs in 2025"

On March 17, the Hunan Provincial Medical Insurance Bureau issued the "Notice on Carrying Out Price Correction for the First Batch of Listed Drugs in 2025." The notice stated that based on the data issued by the National Medical Insurance Bureau and the drug listing data of our province as of March 9, 2025, we will now carry out price correction for the first batch of drugs listed in 2025 that have inverted prices or clearly do not meet price management requirements. This price correction mainly targets three scenarios: "price inversion among different quality levels," "significant price differences in the smallest formulation unit with different packaging numbers for the same manufacturer, generic name, actual dosage form, quality level, and specification," and "price inversion for different specifications of products from the same manufacturer with the same generic name, actual dosage form, and quality level." (Source: Menet)